Oxidative Medicine and Cellular Longevity / 2020 / Article / Fig 6

Research Article

Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways

Figure 6

Trastuzumab in combination with brusatol potently induced apoptosis in BT-474 and SK-OV-3 cancer cells. (a) Induction of apoptosis of BT-474 cells after control IgG (25 μg/mL), brusatol (5 μM), trastuzumab (25 μg/mL), or the combinatorial treatment for 48 h. Apoptosis ratios were measured by flow cytometry. Data was shown with of three independent experiments. . (b) Induction of apoptosis of SK-OV-3 cells after control IgG (25 μg/mL), brusatol (5 μM), trastuzumab (25 μg/mL), or the combinatorial treatment for 48 h. Apoptosis ratios were measured by flow cytometry. Data was shown with of three independent experiments. .
(a)
(b)

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.